

Christopher G Goetz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9315707/publications.pdf>

Version: 2024-02-01

124
papers

22,229
citations

66336

42
h-index

21539

114
g-index

131
all docs

131
docs citations

131
times ranked

17409
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170. | 3.9 | 4,796 |
| 2 | MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601. | 3.9 | 4,389 |
| 3 | Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707. | 3.9 | 2,497 |
| 4 | Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1020-1028. | 3.9 | 1,739 |
| 5 | Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47. | 3.9 | 1,097 |
| 6 | MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611. | 3.9 | 1,033 |
| 7 | Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007, 22, 2314-2324. | 3.9 | 885 |
| 8 | Levodopa-induced dyskinesias. <i>Movement Disorders</i> , 2007, 22, 1379-1389. | 3.9 | 422 |
| 9 | Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. <i>Movement Disorders</i> , 2005, 20, 523-539. | 3.9 | 327 |
| 10 | The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a008862-a008862. | 6.2 | 266 |
| 11 | Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. <i>Movement Disorders</i> , 2007, 22, 179-186. | 3.9 | 249 |
| 12 | Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 248-257. | 5.3 | 224 |
| 13 | Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. <i>Movement Disorders</i> , 2008, 23, 690-699. | 3.9 | 219 |
| 14 | Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 141. | 9.0 | 211 |
| 15 | The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile. <i>Movement Disorders</i> , 2008, 23, 2398-2403. | 3.9 | 196 |
| 16 | Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608. | 3.9 | 171 |
| 17 | Dystonia rating scales: Critique and recommendations. <i>Movement Disorders</i> , 2013, 28, 874-883. | 3.9 | 150 |
| 18 | Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. <i>Movement Disorders</i> , 2012, 27, 1239-1242. | 3.9 | 148 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | The Malignant Course of "Benign Hallucinations" in Parkinson Disease. Archives of Neurology, 2006, 63, 713. | 4.5 | 147 |
| 20 | Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Movement Disorders, 2018, 33, 208-218. | 3.9 | 138 |
| 21 | Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Movement Disorders, 2009, 24, 551-556. | 3.9 | 130 |
| 22 | Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis. Annals of Neurology, 2008, 64, S81-S92. | 5.3 | 122 |
| 23 | Movement disorder society criteria for clinically established early Parkinson's disease. Movement Disorders, 2018, 33, 1643-1646. | 3.9 | 114 |
| 24 | Placebo influences on dyskinesia in Parkinson's disease. Movement Disorders, 2008, 23, 700-707. | 3.9 | 111 |
| 25 | A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Movement Disorders, 2016, 31, 1373-1380. | 3.9 | 111 |
| 26 | Systematic review of severity scales and screening instruments for tics: Critique and recommendations. Movement Disorders, 2017, 32, 467-473. | 3.9 | 92 |
| 27 | Hallucinations and sleep disorders in PD. Neurology, 2010, 75, 1773-1779. | 1.1 | 90 |
| 28 | Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. Movement Disorders, 2016, 31, 625-631. | 3.9 | 89 |
| 29 | Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. Movement Disorders, 2016, 31, 1455-1465. | 3.9 | 87 |
| 30 | The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurology, The, 2016, 15, 546-548. | 10.2 | 82 |
| 31 | Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. JAMA - Journal of the American Medical Association, 2021, 326, 926. | 7.4 | 80 |
| 32 | Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years. Movement Disorders, 2011, 26, 2196-2200. | 3.9 | 79 |
| 33 | Which dyskinesia scale best detects treatment response?. Movement Disorders, 2013, 28, 341-346. | 3.9 | 76 |
| 34 | Assuring interrater reliability for the UPDRS motor section: Utility of the UPDRS teaching tape. Movement Disorders, 2004, 19, 1453-1456. | 3.9 | 73 |
| 35 | Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Annals of Neurology, 2017, 81, 46-57. | 5.3 | 72 |
| 36 | Fatigue in Parkinson's disease: report from a multidisciplinary symposium. Npj Parkinson's Disease, 2016, 2, . | 5.3 | 61 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. <i>Movement Disorders</i> , 2008, 23, 1541-1545. | 3.9 | 59 |
| 38 | I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. <i>Movement Disorders</i> , 2014, 29, 115-117. | 3.9 | 55 |
| 39 | Initial management of Parkinson's disease. <i>BMJ, The</i> , 2014, 349, g6258-g6258. | 6.0 | 52 |
| 40 | Clinical validation of movement disorder society's recommended diagnostic criteria for Parkinson's disease with dementia. <i>Movement Disorders</i> , 2012, 27, 248-253. | 3.9 | 51 |
| 41 | Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019, 34, 791-798. | 3.9 | 49 |
| 42 | Teaching program for the movement disorder society's sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). <i>Movement Disorders</i> , 2010, 25, 1190-1194. | 3.9 | 48 |
| 43 | Official Japanese Version of the International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale: Validation Against the Original English Version. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 200-212. | 1.5 | 47 |
| 44 | Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 83-89. | 2.2 | 46 |
| 45 | Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. <i>Annals of Neurology</i> , 2022, 91, 424-435. | 5.3 | 46 |
| 46 | Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627. | 3.9 | 43 |
| 47 | The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681. | 3.9 | 43 |
| 48 | J.-M. Charcot and simulated neurologic disease. <i>Neurology</i> , 2007, 69, 103-109. | 1.1 | 41 |
| 49 | Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. <i>Movement Disorders</i> , 2006, 21, 267-270. | 3.9 | 40 |
| 50 | Jean-Martin Charcot and his vibratory chair for Parkinson disease. <i>Neurology</i> , 2009, 73, 475-478. | 1.1 | 39 |
| 51 | New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, S104-9. | 3.9 | 39 |
| 52 | Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1135-1139. | 2.2 | 38 |
| 53 | Rating scales for cognition in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 187-195. | 3.9 | 38 |
| 54 | Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 465-471. | 1.5 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Clinimetric testing of the comprehensive cervical dystonia rating scale. <i>Movement Disorders</i> , 2016, 31, 563-569. | 3.9 | 36 |
| 56 | Movement Disorder Society's Unified Parkinson's Disease Rating Scale Use in the Covid-19 Era. <i>Movement Disorders</i> , 2020, 35, 911-911. | 3.9 | 34 |
| 57 | Handling missing values in the MDS-UPDRS. <i>Movement Disorders</i> , 2015, 30, 1632-1638. | 3.9 | 33 |
| 58 | Validation study of the hoehn and yahr scale included in the MDS-UPDRS. <i>Movement Disorders</i> , 2018, 33, 651-652. | 3.9 | 32 |
| 59 | Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 11-22. | 3.9 | 31 |
| 60 | The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661. | 3.9 | 31 |
| 61 | <sc>IPMDS</sc>'s Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the <sc>MDS</sc>'s <sc>UPDRS</sc> and UDysRS. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 97-101. | 1.5 | 30 |
| 62 | Cross-Cultural Differences of the Non-Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 68-77. | 1.5 | 29 |
| 63 | Scales to evaluate psychosis in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S38-S41. | 2.2 | 27 |
| 64 | Evaluating Parkinson's disease patients at home: Utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. <i>Movement Disorders</i> , 2008, 23, 1479-1482. | 3.9 | 24 |
| 65 | Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life. <i>Movement Disorders</i> , 2018, 33, 742-749. | 3.9 | 23 |
| 66 | Telemedicine Use for Movement Disorders: A Global Survey. <i>Telemedicine Journal and E-Health</i> , 2018, 24, 979-992. | 2.8 | 22 |
| 67 | COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?. <i>Journal of Parkinson's Disease</i> , 2021, 11, 3-8. | 2.8 | 21 |
| 68 | Temporal stability of the Unified Dyskinesia Rating Scale. <i>Movement Disorders</i> , 2011, 26, 2556-2559. | 3.9 | 20 |
| 69 | Item Response Theory Analysis of the <sc>MDS</sc>'s <sc>UPDRS</sc> Motor Examination: Tremor vs. Nontremor Items. <i>Movement Disorders</i> , 2020, 35, 1587-1595. | 3.9 | 18 |
| 70 | Chapter 15 Jean-Martin Charcot and the anatomo-clinical method of neurology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2009, 95, 203-212. | 1.8 | 13 |
| 71 | Using Cognitive Pretesting in Scale Development for Parkinson's Disease: The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Example. <i>Journal of Parkinson's Disease</i> , 2014, 4, 395-404. | 2.8 | 12 |
| 72 | Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. <i>Movement Disorders</i> , 2017, 32, 1335-1336. | 3.9 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Head tremor and pain in cervical dystonia. <i>Journal of Neurology</i> , 2021, 268, 1945-1950. | 3.6 | 12 |
| 74 | Non-motor phenotypic subgroups in adult-onset idiopathic, isolated, focal cervical dystonia. <i>Brain and Behavior</i> , 2021, 11, e2292. | 2.2 | 11 |
| 75 | Teaching program for the Unified Dyskinesia Rating Scale. <i>Movement Disorders</i> , 2009, 24, 1296-1298. | 3.9 | 10 |
| 76 | Postural Directionality and Head Tremor in Cervical Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, . | 2.0 | 10 |
| 77 | Validation of the Hebrew version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 7-12. | 2.2 | 9 |
| 78 | Validation of the Polish version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). <i>Neurologia i Neurochirurgia Polska</i> , 2020, 54, 416-425. | 1.2 | 9 |
| 79 | Hold that pose: capturing cervical dystonia's head deviation severity from video. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 684-694. | 3.7 | 9 |
| 80 | Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 335-342. | 4.2 | 9 |
| 81 | Does seasonal variation affect hallucinations in PD? a longitudinal study. <i>Movement Disorders</i> , 2006, 21, 863-865. | 3.9 | 8 |
| 82 | Shaking up the Salpetriere: Jean-Martin Charcot and mercury-induced tremor. <i>Neurology</i> , 2010, 74, 1739-1742. | 1.1 | 7 |
| 83 | Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. <i>Movement Disorders</i> , 2014, 29, 1252-1257. | 3.9 | 7 |
| 84 | Attenuated Postprandial GLP-1 Response in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 660942. | 2.8 | 7 |
| 85 | Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change. <i>Movement Disorders</i> , 2021, 36, 2853-2861. | 3.9 | 7 |
| 86 | Medical-legal issues in Charcot's neurologic career. <i>Neurology</i> , 2004, 62, 1827-1833. | 1.1 | 6 |
| 87 | Independent Spanish Validation of the Unified Dyskinesia Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 213-218. | 1.5 | 6 |
| 88 | It's tricky: Rating alleviating maneuvers in cervical dystonia. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117205. | 0.6 | 6 |
| 89 | Head tremor in cervical dystonia: Quantifying severity with computer vision. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120154. | 0.6 | 6 |
| 90 | Charcot in Contemporary Literature. <i>Journal of the History of the Neurosciences</i> , 2006, 15, 22-30. | 0.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Differential item functioning in the Unified Dyskinesia Rating Scale (UDysRS). <i>Movement Disorders</i> , 2017, 32, 1244-1249. | 3.9 | 5 |
| 92 | Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. <i>Movement Disorders</i> , 2016, 31, 1865-1873. | 3.9 | 4 |
| 93 | Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale. <i>Journal of Movement Disorders</i> , 2022, 15, 151-155. | 1.3 | 4 |
| 94 | Jean-Martin Charcot (1825-1893). <i>Journal of Neurology</i> , 2005, 252, 374-375. | 3.6 | 3 |
| 95 | The Movement Disorder Society and Movement Disorders: A Modern History. <i>Movement Disorders</i> , 2011, 26, 939-946. | 3.9 | 3 |
| 96 | Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia?. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 21. | 2.0 | 3 |
| 97 | Is Telemedicine the New Normal or Is the Office Visit Still the Movement Disorder Option of Choice?. <i>Movement Disorders</i> , 2021, 36, 1481-1482. | 3.9 | 3 |
| 98 | Are Virtual Objective Assessments of Fall Risk Feasible and Safe for People with Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 799-804. | 1.5 | 3 |
| 99 | Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. <i>Movement Disorders</i> , 2022, 37, 1749-1755. | 3.9 | 3 |
| 100 | Movement disorders: understanding clinical trials. <i>Lancet Neurology</i> , The, 2005, 4, 5-6. | 10.2 | 2 |
| 101 | Early cinematographic studies of generalized dystonia. <i>Movement Disorders</i> , 2006, 21, 1561-1565. | 3.9 | 2 |
| 102 | Treating melancholia at home. <i>Neurology</i> , 2013, 80, 1710-1714. | 1.1 | 2 |
| 103 | Closing the celebration of 200 years of Parkinson's <i>Essay on the Shaking Palsy</i>: Where do we go in the next 200 years?. <i>Movement Disorders</i> , 2017, 32, 1651-1652. | 3.9 | 2 |
| 104 | Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018, 33, 499-500. | 3.9 | 2 |
| 105 | In Support of Electronic Versions of <sc>Movement Disorder Society</sc> Rating Scales. <i>Movement Disorders</i> , 2021, 36, 270-271. | 3.9 | 2 |
| 106 | Validation of the Arabic Version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders</i> , 2022, 37, 826-841. | 3.9 | 2 |
| 107 | Charcot and Pasteur: Intersecting Orbits in <i>Fin de Si cle</i> French Medicine. <i>Journal of the History of the Neurosciences</i> , 2009, 18, 378-386. | 0.9 | 1 |
| 108 | Apathy in Parkinson disease. <i>Neurology</i> , 2020, 95, 893-894. | 1.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale. <i>Neuroepidemiology</i> , 2020, 54, 356-362. | 2.3 | 1 |
| 110 | Remembrance of Things Past: A Critical Step in Changing our Future. <i>Annals of Neurology</i> , 2021, 90, 521-523. | 5.3 | 1 |
| 111 | Rating scales for medication adherence in people living with Parkinson's disease. <i>JB I Evidence Synthesis</i> , 2021, Publish Ahead of Print, . | 1.3 | 1 |
| 112 | Two faces of the teacher: Comparing editions of Charcot's <i>Leçons du mardi</i> . <i>Journal of the History of the Neurosciences</i> , 2022, 31, 512-523. | 0.9 | 1 |
| 113 | Implementation and Outcomes of a Movement Disorder Society-sponsored Peer Reviewing Education and Mentoring Program. <i>Movement Disorders</i> , 2022, 37, 1093-1097. | 3.9 | 1 |
| 114 | Greeting from the new editors. <i>Movement Disorders</i> , 2004, 19, 1-1. | 3.9 | 0 |
| 115 | Approach to the patient presenting with parkinsonism. , 2005, , 551-560. | | 0 |
| 116 | Neuroleptic-Induced Movement Disorders. , 2008, , 371-387. | | 0 |
| 117 | In Memory of Dr. William J. Weiner. <i>Current Treatment Options in Neurology</i> , 2013, 15, 375-376. | 1.8 | 0 |
| 118 | Babinski's contributions to cerebellar symptomatology: building the basis of the neurological examination. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 973-975. | 0.8 | 0 |
| 119 | Preface. <i>Movement Disorders</i> , 2015, 30, 1441-1441. | 3.9 | 0 |
| 120 | Response to letter by Saenz-Farret et al. on "Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations". <i>Movement Disorders</i> , 2017, 32, 482-482. | 3.9 | 0 |
| 121 | Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders</i> , 2018, 33, 1189-1190. | 3.9 | 0 |
| 122 | Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 113-116. | 2.2 | 0 |
| 123 | Validation of the Polish version of the Unified Dyskinesia Rating Scale (UDysRS). <i>Neurologia I Neurochirurgia Polska</i> , 2021, 55, 186-194. | 1.2 | 0 |
| 124 | Validation of the Finnish Version of the Unified Dyskinesia Rating Scale. <i>European Neurology</i> , 2021, 84, 444-449. | 1.4 | 0 |